Satellos Bioscience (MSLE) vs Tiziana Life Sciences (TLSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Satellos Bioscience (MSLE) has outperformed Tiziana Life Sciences (TLSA) over the past year, gaining 5.4% versus a loss of 50.7%. Over five years, TLSA leads with a -25.2% price change compared with -48.9% for MSLE. Satellos Bioscience is the larger company by market cap ($155.8 million vs $143.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MSLE | TLSA |
|---|---|---|
| Share price | $7.35 | $1.13 |
| Market cap | $155.83M | $143.80M |
| 1-day change | -3.74% | +2.73% |
| YTD return | +29.76% | -24.16% |
| 1-year return | +5.44% | -50.66% |
| 5-year return | -48.93% | -25.17% |
| EPS (TTM) | $-1.95 | $-0.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.40 | $2.25 |
| 52-week low | $5.30 | $0.76 |
| Distance from 52-week high | -45.17% | -49.78% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +251.26% | +606.19% |
| Average volume | 50.10K | 720.16K |
| Shares outstanding | 21.22M | 127.26M |
| Employees | 18 | 10 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MSLE has outperformed TLSA by 56.1 percentage points over the past year.
- The two companies sit in different sectors: Satellos Bioscience in Healthcare and Tiziana Life Sciences in Health Care.
About Satellos Bioscience
MSLE stock →Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo.
Healthcare · Biotechnology · 18 employees
About Tiziana Life Sciences
TLSA stock →Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
MSLE vs TLSA FAQ
Which is bigger, Satellos Bioscience or Tiziana Life Sciences?
Satellos Bioscience (MSLE) is larger, with a market capitalization of $155.83M compared with $143.80M for Tiziana Life Sciences (TLSA).
Which stock has performed better over the past year, MSLE or TLSA?
MSLE returned +5.44% over the past 12 months, compared with -50.66% for TLSA (price return, excluding dividends). Past performance does not predict future results.
Are Satellos Bioscience and Tiziana Life Sciences in the same industry?
No. Satellos Bioscience is in the Healthcare sector, while Tiziana Life Sciences is in Health Care.